Ranibizumab for Neovascularization in Sickle Cell Retinopathy

• Status: Withdrawn
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the ocular and non-ocular safety of a single dose of ranibizumab in treating neovascularization secondary to sickle cell retinopathy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kresge Eye Institute
• Collaborators: Genentech, Inc.; Wayne State University
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Patients with sickle cell anemia and retinopathy

• Over age 18 years

• Non-pregnant

Exclusion Criteria:

• Pregnant

• Glaucoma

• Patients using anticoagulants (e.g., warfarin)

• Retinal detachment